Two lactating Nubian goats were dermally treated with [14C]coumaphos (O-[3-chloro-4-methyl-2-oxo-2H-benzopyran-7-yl] O,O-diethyl phosphorothioate) as a 4% active ingredient pour-on formulation. Doses were administered, along the dorsal midline from withers to sacrum, at a rate equivalent to 14 mg of coumaphos/kg of body weight. During the 7 days after treatment, an average of less than 0.1, 4.7, and 1% of the administered dose was eliminated in the milk, urine, and feces, respectively. When goats were killed after 7 days, about 45% of the administered radiocarbon remained on the hair and skin, and this consisted almost entirely of intact coumaphos. Residues in selected tissues collected after 7 days were, in every case, less than 1 mg of coumaphos equivalent/kg of tissue, with highest residues in adipose tissue, followed by residues in kidney and liver. In milk, residue amounts plateaued after about 2 days and remained relatively constant at about 0.1 mg of coumaphos equivalent/kg of milk. Residues in adipose tissue and in milk consisted mainly of unmetabolized coumaphos. In urine, most radiocarbon was present as metabolites of coumaphos, but in feces, most radiocarbon was present as the intact parent compound. Coumaphos was absorbed slowly and at a constant rate after dermal application to lactating goats as a pour-on formulation.
Download Full PDF Version (Non-Commercial Use)